Still, CEO Doug Ingram claimed removing the two drugs, Vyondys 53 and Amondys 45, from market would make “little sense” and ...
The startup claims its medicines may be able to overcome the limitations of conventional antibody-drug conjugates by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback